Maturitas最新文献

{"title":"The feasibility and effects of a telehealth-delivered physical therapy program for postmenopausal women with urinary incontinence: A pilot mixed-methods study","authors":"Kuan-Yin Lin ,&nbsp;Chao-Yin Chen ,&nbsp;Pei-Chi Wu ,&nbsp;Min-Hsuan Huang ,&nbsp;Yin-Chien Ou ,&nbsp;Yao-Lin Kao ,&nbsp;Kuan-Han Lin","doi":"10.1016/j.maturitas.2025.108376","DOIUrl":"10.1016/j.maturitas.2025.108376","url":null,"abstract":"<div><h3>Objectives</h3><div>This study investigated the feasibility and effectiveness of a telehealth-delivered pelvic floor muscle training program for postmenopausal women with urinary incontinence, in comparison with face-to-face pelvic floor muscle training.</div></div><div><h3>Stud design</h3><div>This was a pilot mixed-methods study that included a non-inferiority randomized controlled trial with a nested qualitative study. Community-dwelling postmenopausal women (&gt;40 years) with urinary incontinence were recruited and randomly allocated to 12 weeks of telehealth or face-to-face pelvic floor muscle training. The face-to-face group received supervised training twice weekly, while the telehealth group had eight virtual sessions plus weekly telephone coaching.</div></div><div><h3>Main outcome measures</h3><div>Assessments at baseline, post-intervention, and three-month follow-up included feasibility, anthropometry, body composition, hand grip strength, functional exercise capacity, physical activity levels, the severity of urinary incontinence, and pelvic floor muscle function (assessed through vaginal manometry, transperineal ultrasound, and digital palpation).</div></div><div><h3>Results</h3><div>Among 55 potential participants, 22 enrolled (40 % consent rate). Attendance was 100 %, with 63.3 % adherence to the home program. Satisfaction was high (very satisfied: 71 % face-to-face, 89 % telehealth). Both groups reported increased confidence in pelvic floor muscle training. Urinary symptoms and pelvic floor function improved in both groups, with benefits sustained at three months. Telehealth pelvic floor muscle training also enhanced grip strength. No significant differences were found between groups.</div></div><div><h3>Conclusions</h3><div>Telehealth pelvic floor muscle training appears to be a feasible and potentially effective alternative to face-to-face therapy for postmenopausal women with urinary incontinence. Larger studies are needed to confirm these preliminary findings and guide future interventions.</div></div><div><h3>Trial registration</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (<span><span>NCT05970796</span><svg><path></path></svg></span>); date of registration: 29/07/2023.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"197 ","pages":"Article 108376"},"PeriodicalIF":3.9,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143867904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the use of menopausal hormone therapy in France, 2001–2023","authors":"Rafael Amaro Costa ,&nbsp;Ana-Maria Vilcu ,&nbsp;Manon Cairat ,&nbsp;Eléa Olivier ,&nbsp;Anne C.M. Thiébaut ,&nbsp;Agnès Fournier","doi":"10.1016/j.maturitas.2025.108270","DOIUrl":"10.1016/j.maturitas.2025.108270","url":null,"abstract":"<div><h3>Objectives</h3><div>Few studies have examined trends in the use of menopausal hormone therapy (MHT) from the early 2010s onwards. Furthermore, data from the period after the release of the results of the Women's Health Initiative in 2002 are rarely reported with a distinction between systemic and local MHT. We therefore describe trends in the use of systemic and local MHT in France during the period 2001–2023.</div></div><div><h3>Study design</h3><div>Descriptive study using annual drug claim data aggregated at the national level from two French open-source databases.</div></div><div><h3>Main outcome measures</h3><div>The annual (2001-2023) number of estrogen-based MHT boxes reimbursed by the French National Health Insurance system was extracted and classified according to the route of administration. From 2014 onwards, data on the number of consumers of each estrogen-based MHT preparation, available by age categories, was used to further estimate the number of individuals using MHT, overall and by MHT type (systemic/local).</div></div><div><h3>Results</h3><div>The annual number of MHT claims fell from 25.0 to 6.3 million boxes between 2001 and 2023. Systemic MHT products almost exclusively accounted for this fall, while local MHT use remained rather stable. We estimated that, in 2023, local MHT was used by 1.1 million individuals (0.44 million aged 20–59 years and 0.67 aged 60+ years) and systemic MHT by 0.5 million (0.37 million aged 20–59 years and 0.16 million aged 60+ years).</div></div><div><h3>Conclusions</h3><div>In France, the use of systemic MHT has plummeted since 2001, while use of local MHT has remained stable. Claims for local MHT now represent more than half of all MHT claims in France.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"197 ","pages":"Article 108270"},"PeriodicalIF":3.9,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143860069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life at peri- and postmenopause: analysis of the results from app “Mi Menopausia”","authors":"Pluvio J. Coronado ,&nbsp;María Fasero ,&nbsp;Nicolás Mendoza ,&nbsp;Silvia P. González ,&nbsp;Sonia Sánchez-Méndez ,&nbsp;Jesús Presa ,&nbsp;Ana R. Jurado ,&nbsp;Esther de la Viuda ,&nbsp;Francisco Quereda ,&nbsp;on behalf of REIM (“Red Española de Investigación en Menopausia”)","doi":"10.1016/j.maturitas.2025.108267","DOIUrl":"10.1016/j.maturitas.2025.108267","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the health-related quality of life (HRQOL) of Spanish peri- and postmenopausal women using the Cervantes Short Form (SF) scale, and the factors associated with its variations.</div></div><div><h3>Study design</h3><div>A total of 7103 peri- and postmenopausal women were registered with the app “Mi Menopausia” from June 2021 to June 2024. This app is designed specifically for peri- and postmenopausal women. It measures HRQOL using the Cervantes SF scale (higher scores indicate lower HRQOL). Data collected included demographic information, lifestyle details, menopause symptoms, treatments for symptom relief, and personal medical history.</div></div><div><h3>Results</h3><div>Of the 6833 women included in the final analysis, 47.9 % were peri- and 52.1 % postmenopausal. The overall Cervantes SF score was 40.1 ± 16.8 and was associated in multivariant analysis with age (B: −0.29, 95 % confidence interval (CI): −0.36 to −0.21), obesity (B: 1.68; 95CI: 0.44 to 2.93), postmenopausal status (B: 1.11; 95CI: 0.22 to 2.0), education level (B: -1.05; 95CI: −1.91 to −0.19), having a partner (B: -2.76; 95CI: −4.03 to −1.49), sexual intercourse (B: -8.25; 95CI: −9.81 to −6.69), no sexual activity (B: 5.86; 95CI: 3.91 to 7.81), diagnosis of depression (B: 8.34; 95CI: 7.34 to 9.35), having undergone hysterectomy (B: 0.51; 95CI: 0.10 to 3.64) and oophorectomy (B: 0.90; 95CI: 0.10 to 3.64) and having experienced bone fractures (B: 0.71; 95CI: 0.12 to 2.90).</div></div><div><h3>Conclusion</h3><div>The HRQOL of peri- and postmenopausal Spanish women is complex but improvable and is associated with various factors, particularly related to sexual activity and a diagnosis of depression or anxiety.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"197 ","pages":"Article 108267"},"PeriodicalIF":3.9,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143860182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endometriosis as a risk factor for age-related macular degeneration: A nationwide population-based study and genetic aspects","authors":"Maria I. Zervou ,&nbsp;Basil C. Tarlatzis ,&nbsp;George N. Goulielmos","doi":"10.1016/j.maturitas.2025.108272","DOIUrl":"10.1016/j.maturitas.2025.108272","url":null,"abstract":"","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"197 ","pages":"Article 108272"},"PeriodicalIF":3.9,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143860070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A smartphone model for post-acute care decreases all-cause mortality with improved left ventricular ejection fraction in patients hospitalized with heart failure in Taiwan","authors":"Shuo-Chun Weng ,&nbsp;Wei-Wen Lin ,&nbsp;Jin-Long Huang ,&nbsp;Chin-Yi Chao ,&nbsp;Chiann-Yi Hsu ,&nbsp;Shih-Yi Lin","doi":"10.1016/j.maturitas.2025.108269","DOIUrl":"10.1016/j.maturitas.2025.108269","url":null,"abstract":"<div><h3>Objectives</h3><div>This study investigates the impact of the use of a smartphone application on outcomes for patients with heart failure receiving post-acute care.</div></div><div><h3>Methods</h3><div>We employed a propensity score-matched analysis of patients who underwent post-acute care following hospitalization for heart failure. The smartphone application consisted of immediate feedback, recommendations, and a knowledge platform. We assessed seven variables before and after post-acute care: left ventricular ejection fraction, and scores on the Minnesota Living with Heart Failure Questionnaire, Mini-Nutritional Assessment–Short Form, Instrumental Activities of Daily Living, Brief Symptom Rating Scale-5, 6-minute walk test, and European Quality of Life-5 Dimensions Questionnaire. The functional progression dose effect was evaluated using receiver operating characteristic curves. Application users and non-users were matched to minimize the impacts of confounding variables, including age, gender, and education. The Cox proportional hazards model and the sub-distribution hazard method assessed the impact of the smartphone application on post-discharge outcomes.</div></div><div><h3>Results</h3><div>From 2018 to 2023, 493 patients (average age 65.4 ± 15.1 years) participated in the study. Over an average follow-up of 2.35 years, the results indicated that each additional unit of functional improvement was associated with a 38 % reduction in overall mortality, a 23 % decrease in readmissions or emergency room visits, and a 36 % lower risk of cardiovascular mortality. Among 119 matched pairs, application users demonstrated significantly lower mortality risk and better left ventricular ejection fraction than non-users. Kaplan-Meier curves showed that application users with improved left ventricular ejection fraction had the best survival outcomes, followed by non-application users with improved left ventricular ejection fraction, application users without improved left ventricular ejection fraction, and non-application users without improved left ventricular ejection fraction (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The findings suggest that smartphone applications could enhance transitional care for patients with heart failure by improving left ventricular ejection fraction and reducing mortality.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"197 ","pages":"Article 108269"},"PeriodicalIF":3.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143843705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyaluronic acid injection to treat symptoms of vulvovaginal atrophy in postmenopausal women: A 12-week randomised, placebo-controlled, multicentric study","authors":"Fabienne Marchand Lamiraud ,&nbsp;Hichem Bensmail ,&nbsp;Carine Martin ,&nbsp;Sofie Pelckmans ,&nbsp;Firas Cha'ban ,&nbsp;Aliette Siboni Frisch ,&nbsp;Gulcan Deniz ,&nbsp;Pascale Sabban Serfati ,&nbsp;Brigitte Caubo ,&nbsp;Brice Gurriet ,&nbsp;Isabelle Petit Breuilh ,&nbsp;Ann Inge Pastijn ,&nbsp;Nicolas Berreni ,&nbsp;Michel Cosson","doi":"10.1016/j.maturitas.2025.108264","DOIUrl":"10.1016/j.maturitas.2025.108264","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the efficacy and safety of a single injection session of cross-linked hyaluronic acid gel for vulvovaginal atrophy, versus placebo.</div></div><div><h3>Design</h3><div>Two-step study comprising a 12-week randomised, placebo-controlled, single-blind phase, followed by an open-label phase. Eligible postmenopausal women with vulvovaginal atrophy were randomised (2:1) to a single injection session of either hyaluronic acid or placebo. This is the report of the single-blind phase.</div></div><div><h3>Main outcome measures</h3><div>The primary outcome was the mean change in the severity score for the most bothersome symptom at 12 weeks compared with baseline. Secondary outcomes included differences in scores for individual vulvovaginal atrophy symptoms, score on the Female Sexual Function Index and vaginal pH.</div></div><div><h3>Results</h3><div>A total of 116 of the 117 patients in the randomised population contributed outcome data to the study (79 receiving hyaluronic acid and 37 placebo). Compared with baseline, the mean score for the severity of the most bothersome symptom was significantly reduced in the hyaluronic acid arm at 12 weeks (between-group difference [95 % confidence interval]: −0.58 [−1.01; −0.16], p = 0.008). Similarly, there were significant reductions in mean scores for dryness (−0.87 [−1.27; −0.47]; p &lt; 0.001) and dyspareunia (−0.65 [−1.09; −0.21]; p = 0.004) and improvement in score on the Female Sexual Function Index (3.81 [0.91; 6.72]; p = 0.011) in the hyaluronic acid group. There were no differences in itching/irritation, pain or vaginal pH in either group. Hyaluronic acid treatment was well tolerated.</div></div><div><h3>Conclusions</h3><div>A single injection session of cross-linked hyaluronic acid is effective in reducing vulvovaginal symptoms and sexual dysfunction compared with placebo at 12 weeks, making it a suitable management option for moderate to severe vulvovaginal atrophy symptoms.</div></div><div><h3>Trial registration</h3><div>NCT 04219722 (<span><span>https://clinicaltrials.gov/study/NCT04219722</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"197 ","pages":"Article 108264"},"PeriodicalIF":3.9,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143860181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xerostomia and oral health-related quality of life in peri- and postmenopausal women","authors":"Pascual García-Alfaro ,&nbsp;Faustino R. Pérez-López ,&nbsp;Sandra García Martínez ,&nbsp;Ignacio Rodríguez","doi":"10.1016/j.maturitas.2025.108268","DOIUrl":"10.1016/j.maturitas.2025.108268","url":null,"abstract":"<div><h3>Objective</h3><div>The menopausal transition triggers hormonal changes that can manifest in oral symptoms such as xerostomia, which can substantially impact women's quality of life. Our study examined the prevalence and severity of xerostomia and its association with menopausal status. Furthermore, we evaluated the impact of xerostomia on oral health-related quality of life in peri- and postmenopausal women.</div></div><div><h3>Methods</h3><div>This study was a cross-sectional investigation based on the results of a REDCap survey, involving 3211 women aged between 40 and 90 years. The survey recorded age, menopause status, age at menopause, smoking status, and being treated with xerogenic drugs and included two instruments: the Xerostomia Inventory, used to evaluate the oral symptoms; and the Oral Health Impact Profile-14 (OHIP-14), used to assess the related quality of life. Student's <em>t</em>-test, the chi-squared test, Pearson's correlation coefficient, and multivariable logistic and linear regressions were performed for data analysis. Odds ratio (OR), beta coefficient (β), and their 95 % confidence intervals (CIs) were applied to assess associations.</div></div><div><h3>Results</h3><div>The global prevalence of xerostomia was 71.2 %. The Xerostomia Inventory score correlated with the OHIP-14 score (<em>r</em> = 0.686; <em>p</em> = 0.000). Smoking was significantly associated with the probability of xerostomia (OR = 1.36; 95 % CI = 1.02–1.82), as were the following OHIP-14 domains: functional limitation (OR = 1.43; 95 % CI = 1.30–1.50), physical pain (OR = 1.17; 95 % CI = 1.06–1.29), psychological discomfort (OR = 1.21; 95 % CI = 1.13–1.29), physical disability (OR = 1.11; 95 % CI = 1.02–1.20), psychological disability (OR = 1.18; 95 % CI = 1.09–1.29), and social disability (OR = 1.15; 95 % CI = 1.01–1.32). There were no significant differences in the probability of xerostomia according to the menopausal status. In women with xerostomia the OHIP-14 score was higher than in women without xerostomia (β = 5.50; 95 % CI = 4.69–6.31).</div></div><div><h3>Conclusions</h3><div>Peri- and postmenopausal women have a high prevalence of xerostomia. There were no differences in the probability of xerostomia between peri- and postmenopausal women. There was a strong association between xerostomia symptoms and poor oral health-related quality of life.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"197 ","pages":"Article 108268"},"PeriodicalIF":3.9,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"State anxiety is associated with hormonal, cardiovascular, and sleep parameters in Finnish postmenopausal women","authors":"Ville Rimpilä ,&nbsp;Tero Vahlberg ,&nbsp;Katja Valli ,&nbsp;Tarja Saaresranta","doi":"10.1016/j.maturitas.2025.108266","DOIUrl":"10.1016/j.maturitas.2025.108266","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate how a range of variables, both physiological (sleep architecture, serum follicle-stimulating hormone (S-FSH), anthropometric and blood pressure measures) and non-physiological (stressful life events, education), are associated with symptoms of distress, anxiety, and depression from premenopause to postmenopause and at postmenopause.</div></div><div><h3>Methods</h3><div>We recruited 64 women (ages 45–47). Data were derived from an in-house questionnaire, the Brief Symptom Inventory, State-Trait Anxiety Inventory, Beck Depression Inventory, a sleep questionnaire, physiological measurements, and polysomnography at baseline and at ten-year follow-up.</div></div><div><h3>Results</h3><div>During the follow-up, an increase in weight was associated with an increase in anxiety as recorded by the Brief Symptom Inventory (p = 0.012, R² = 0.117). Cross-sectionally, at postmenopause, state anxiety was associated with an increase in blood pressure and S-FSH, delayed REM sleep, and the use of menopausal hormone therapy (p_STAI-S &lt; 0.001, R² = 0.343). Distress and depressive symptoms were associated with stressful life events and a lower level of education but also with an increase in diastolic blood pressure and use of hormone therapy (p_BSI &lt; 0.001, R² = 0.328 and p_BDI &lt; 0.001, R² = 0.312). Sleep disruptions were associated with psychological symptoms but vasomotor symptoms were not.</div></div><div><h3>Conclusions</h3><div>The change in psychological symptoms during the follow-up was modest. At postmenopause, distress and depressive symptoms were associated with a range of physiological and non-physiological parameters, but state anxiety only with physiological parameters. At postmenopause, psychological symptoms were more sensitive to sleep disruptions than were vasomotor symptoms.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"197 ","pages":"Article 108266"},"PeriodicalIF":3.9,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No increased arterial stiffness after premenopausal risk-reducing salpingo-oophorectomy (RRSO)","authors":"Maarten J. Beekman ,&nbsp;Lara Terra ,&nbsp;Jeanine E. Roeters van Lennep ,&nbsp;Bernadette A.M. Heemskerk-Gerritsen ,&nbsp;Marc van Beurden ,&nbsp;Helena C. van Doorn ,&nbsp;Joanne A. de Hullu ,&nbsp;Eleonora B.L. van Dorst ,&nbsp;Constantijne H. Mom ,&nbsp;Brigitte F.M. Slangen ,&nbsp;Marian J.E. Mourits ,&nbsp;Katja N. Gaarenstroom ,&nbsp;Klaartje van Engelen ,&nbsp;Lizet E. van der Kolk ,&nbsp;J. Margriet Collée ,&nbsp;Marijke R. Wevers ,&nbsp;Margreet G.E.M. Ausems ,&nbsp;Lieke P.V. Berger ,&nbsp;Encarna B. Gomez Garcia ,&nbsp;Christi J. van Asperen ,&nbsp;Angela H.E.M. Maas","doi":"10.1016/j.maturitas.2025.108265","DOIUrl":"10.1016/j.maturitas.2025.108265","url":null,"abstract":"<div><h3>Objective</h3><div>Women at high familial risk of ovarian cancer are recommended to undergo premenopausal risk-reducing salpingo-oophorectomy (RRSO). The procedure leads to immediate surgical menopause, and while early natural menopause is associated with an increase in the risk of cardiovascular disease (CVD), evidence on CVD risk after surgical menopause is inconsistent.</div></div><div><h3>Main outcome measures</h3><div>To investigate the long-term CVD risk after surgical menopause we conducted a cross-sectional study comparing a group of women who underwent a premenopausal RRSO (≤45 years) with a group who underwent postmenopausal RRSO (≥54 years). We assessed arterial stiffness, measured by pulse wave velocity (PWV). Increased PWV has been shown to be an independent predictor for CVD. Age differences between the pre- and postmenopausal RRSO groups were accounted for by restricting analyses to women aged 60–70 at study visit (n = 307). Within the premenopausal RRSO group (n = 461), we also examined the effect of timing of premenopausal RRSO on PWV (RRSO&lt;41 vs RRSO 41–45 years). In addition, we assessed the association between PWV and coronary artery calcium (CAC) in women who underwent premenopausal RRSO.</div></div><div><h3>Results</h3><div>In women aged 60–70 at study visit, PWV levels were significantly lower in the premenopausal RRSO group compared with the postmenopausal RRSO group (β: -0.87, 95 % CI, −1.45, −0.28 for PWV level; RR: 0.47, 95 % CI, 0.24, 0.93 for being in the upper PWV quintile). The timing of premenopausal RRSO did not influence PWV. Among all women who underwent premenopausal RRSO, having a PWV in the upper quintile was an independent predictor of the presence of CAC (RR 1.32, 95 % CI, 1.04–1.68 for CAC &gt; 0).</div></div><div><h3>Conclusion</h3><div>Our study does not support a long-term adverse effect of premenopausal RRSO on arterial stiffness, but increased arterial stiffness is associated with the presence of CAC in women who have undergone a premenopausal RRSO.</div></div><div><h3>Clinical trial registration</h3><div>The pre-registered clinical trial number is &lt;NCT03835793&gt;.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"197 ","pages":"Article 108265"},"PeriodicalIF":3.9,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Swedish physicians' knowledge of and prescribing practices for menopausal hormone therapy: A nationwide cross-sectional survey","authors":"Rebecca Götze Eriksson ,&nbsp;Alkistis Skalkidou ,&nbsp;Natalia Cruz ,&nbsp;Angelica Lindén Hirschberg ,&nbsp;Stavros I. Iliadis","doi":"10.1016/j.maturitas.2025.108263","DOIUrl":"10.1016/j.maturitas.2025.108263","url":null,"abstract":"<div><h3>Objectives</h3><div>To investigate current prescribing practices, knowledge levels and related disparities regarding menopausal hormone therapy (MHT) among physicians in Sweden.</div></div><div><h3>Study design</h3><div>A 45-item web-based MHT-focused survey conducted February–September 2023. Participants were specialists/residents in obstetrics and gynecology (gynaecologists) and general practitioners (GPs) in Sweden.</div></div><div><h3>Main outcome measures</h3><div>Experience with MHT prescription, prescription patterns and challenges and perceived knowledge of and adherence to national guidelines among gynaecologists and GPs, analyzed quantitatively, along with potential differences between the two groups.</div></div><div><h3>Results</h3><div>In total, 542 physicians answered the survey (67.9 % gynaecologists and 32.1 % GPs). Over 90 % reported meeting women with menopausal symptoms in their clinical practice and among those 94.6 % prescribed systemic MHT. GPs prescribed MHT to a significantly lesser extent than gynaecologists. GPs reported a significantly higher level of difficulty in all but one of the examined aspects of MHT prescription. GPs demonstrated significantly lower awareness of current national guidelines than gynaecologists. Regarding self-perceived assessment of MHT-related education, 47.8 % of GPs, compared with 30.6 % of gynaecologists, reported inadequate theoretical education (p &lt; 0.001). Physicians working in metropolitan areas were more experienced in prescribing micronized progesterone and dydrogesterone.</div></div><div><h3>Conclusions</h3><div>Differences were observed between responding gynaecologists and GPs in MHT-related practices and knowledge. While GPs reported lower awareness of guidelines and encountered more challenges in prescribing MHT, nearly one-third of gynaecologists also indicated inadequate education in MHT. This study underscores the need for improved guideline awareness and accessible education to support evidence-based menopause care for the expanding midlife female population.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"197 ","pages":"Article 108263"},"PeriodicalIF":3.9,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}